Related Experiment Video
Updated: Apr 28, 2026

07:29
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
9.8K
[Conclusive pleuropulmonectomy in patients with pulmonary tuberculosis]
Klinichna Khirurhiia
|June 14, 2014
Summary
Conclusive pleuropulmonectomy (CPPE) demonstrated an 81.3% efficacy in treating multidrug-resistant pulmonary tuberculosis. This surgical approach showed manageable complication rates in patients with advanced lung disease.
Area of Science:
- Pulmonology
- Thoracic Surgery
- Infectious Diseases
Context:
- Multidrug-resistant tuberculosis (MDR-TB) presents significant treatment challenges.
- Surgical interventions are sometimes necessary for advanced or refractory cases of pulmonary tuberculosis.
- Conclusive pleuropulmonectomy (CPPE) is a complex surgical procedure for severe lung conditions.
Purpose:
- To evaluate the performance and outcomes of conclusive pleuropulmonectomy (CPPE) in patients with multidrug-resistant pulmonary tuberculosis.
- To assess the efficacy and complication rates associated with CPPE in this specific patient cohort.
- To analyze the types of pulmonary tuberculosis treated with CPPE.
Summary:
- This study reports on 16 patients who underwent CPPE between 2004 and 2012 for multidrug-resistant pulmonary tuberculosis.
- The majority of patients (75%) had undergone prior atypical pulmonary resection.
- CPPE was primarily performed for fibrous-cavernous tuberculosis (68.8%), followed by cirrhotic tuberculosis (25.0%) and caseous pneumonia (6.3%).
- Intraoperative complication rates were 12.5%, with early and late postoperative complication rates at 31.3% and 18.8%, respectively.
- The overall efficacy of CPPE in this series was 81.3%.
Impact:
- CPPE can be an effective treatment option for carefully selected patients with advanced multidrug-resistant pulmonary tuberculosis.
- Understanding complication rates is crucial for surgical planning and patient management.
- This data contributes to the limited evidence base for surgical management of refractory MDR-TB.
Related Concept Videos
Pneumothorax-II
1.7K
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
1.7K
Pulmonary Tuberculosis V
984
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
984
Pulmonary Tuberculosis I
1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Pulmonary Tuberculosis II
2.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.4K
Pulmonary Tuberculosis III
1.7K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.7K
Pneumonia IV: Management
1.2K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K

